Search clinical trials for: Chidamide, Lenalidomide

Total 1216 results

Leslie Andritsos
Celgene Corporation

Completed

Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

United States
Celgene

Terminated

Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)

Multiple Myeloma

China
Nordic MDS Group

Completed

Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

AML | MDS

Denmark, Norway, Sweden
Winston Laboratories

Completed

Civamide Nasal Solution for the Treatment of Dry Eye

Dry Eye

United States
Peking University

Not yet recruiting

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Peripheral T-cell Lymphoma

China
University Health Network, Toronto
Celgene Corporation

Completed

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

Hodgkin Disease
Yale University
Celgene Corporation

Terminated

Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Celgene Corporation

Completed

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy

Radiculopathy

United States
Fudan University

Unknown

Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Neoplasms | Immune System Diseases | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-Hodgkin | Gemcitabine | Cisplatin | Dexamethasone | Rituximab | Cyclophosphamide | Chidamide | Neoplasm by Histology | HDAC Inhibitor

China
Columbia University
Celgene Corporation

Active, not recruiting

Revlimid in Transfusion Dependent Patients

Myelodysplastic Syndrome

United States
The Lymphoma Academic Research Organisation
Celgene Corporation

Completed

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma (CLEAR)

Relapsed/Refractory B-cell Lymphoma

France
Celgene Corporation

Completed

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Southern Europe New Drug Organization
Celgene Corporation

Unknown

Lenalidomide and Paclitaxel in Advanced Solid Tumors

Advanced Solid Tumors

Switzerland, Italy
Winston Laboratories

Terminated

Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve

Postherpetic Neuralgia

United States
Novartis Pharmaceuticals
Bristol-Myers Squibb

Recruiting

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

United States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
Beijing Friendship Hospital

Recruiting

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

EBV Infection

China
German CLL Study Group
Celgene

Completed

A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

Chronic Lymphocytic Leukemia

Germany
Celgene Corporation

Terminated

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1 (CRPS-002)

Complex Regional Pain Syndrome, Type I

United States
Telik

Completed

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Not yet recruiting

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

B-cell Non-Hodgkin's Lymphoma
The Lymphoma Academic Research Organisation
Centre Henri Becquerel

Completed

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma (R2-CHOP2)

Follicular Lymphoma

France
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia

Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Samyang Biopharmaceuticals Corporation
Chungnam National University Hospital

Completed

Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers

Healthy, Male
Celgene

Completed

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Multiple Myeloma

Ukraine, Russian Federation
King's College Hospital NHS Trust

Completed

The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality

Myelodysplastic Syndromes

United Kingdom
National Cancer Institute (NCI)

Completed

CC-5013 in Treating Patients With Recurrent Glioma

Brain and Central Nervous System Tumors

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

A Phase II Study of CC-5013 in Myelofibrosis

Myelofibrosis

United States
Henan Cancer Hospital

Recruiting

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Central Nervous System Lymphoma

China
Fudan University

Not yet recruiting

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Chinese PLA General Hospital

Recruiting

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Hodgkin Lymphoma | Anti-PD-1 Antibody Resistant

China
Winston Laboratories

Not yet recruiting

Civamide Nasal Solution for Cluster Headache (ECH)

Episodic Cluster Headache
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center; Mayo Clinic; Dana-Farber Cancer Institute and other collaborators

Completed

RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

Unspecified Childhood Solid Tumor, Protocol Specific | Childhood Myelodysplastic Syndromes | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With... and other conditions

United States
Ruijin Hospital

Unknown

Lenalidomide Based Immunotherapy in the Treatment of DLBCL

Diffuse Large B Cell Lymphoma

China
Johns Hopkins All Children's Hospital

Terminated

Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

Central Nervous System Tumors

United States
Lymphoma Study Association

Completed

Lenalidomide and R-CHOP in B-cell Lymphoma (R2CHOP-1)

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma

France
University of Leeds
Celgene Corporation; Oncolytics Biotech; Myeloma UK

Unknown

Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma (MUKeleven)

Multiple Myeloma

United Kingdom
St. Joseph's Hospital and Medical Center, Phoenix
The Cleveland Clinic; National Institute on Aging (NIA)

Recruiting

MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients (MCLENA-1)

Cognitive Dysfunction | Neurodegeneration | Cognitive Impairment, Mild | Amyloid Plaque | Inflammation, Brain

United States
Samsung Medical Center

Recruiting

Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT (KMM1911)

Multiple Myeloma

Korea, Republic of
Marcelo Pasquini, MD
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Active, not recruiting

MM CAR-T to Upgrade Response BMTCTN1902

Multiple Myeloma

United States
Fondazione Italiana Linfomi ONLUS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Completed

Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

MANTLE CELL LYMPHOMA

Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
The First Affiliated Hospital of Xiamen University
Fujian Cancer Hospital; Dongguan People's Hospital; Huizhou Municipal Central... and other collaborators

Recruiting

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Leukemia, Myeloid, Acute | Refractory Leukemia | Relapsed Adult AML

China
Zhujiang Hospital

Recruiting

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Leukemia, Myeloid, Acute

China
Attaya Suvannasankha
Celgene

Completed

Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma

Multiple Myeloma

United States
Bionor Immuno AS
Celgene Corporation

Completed

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (IMID)

HIV-1 Infection

Germany
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital with Nanjing Medical University; Sun Yat-sen... and other collaborators

Recruiting

Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL

Follicular Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma

China

Search clinical trials for: Chidamide, Lenalidomide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations